Mölnlycke Health Care invests in Siren
By HME News Staff
Updated 11:47 AM CST, Wed January 8, 2025
GOTHENBURG, Sweden – Mölnlycke Health Care has announced an $8 million investment in Siren, which makes the Siren sock, a temperature sensing textile technology, to help reduce the risk of diabetic foot ulcers through early detection. “Our strategic investment in Siren reflects our commitment to integrating into digital ecosystems and pioneering innovative digital solutions that revolutionize health care delivery,” says Zlatko Rihter, CEO of Mölnlycke. “Helping to prevent wounds from occurring is also in line with Mölnlycke’s Wound Care mission to ‘help free patients from the burden of wounds’ and our ambition to further support health care in the post-acute segment.” Siren has also created a service ecosystem using remote patient monitoring clinical teams. The company’s system has been clinically proven to reduce the risk of ulcers by up to 68% and amputations by 83%, it says. “We’re excited to team up with Mölnlycke to tackle diabetic foot ulcers at their earliest stages,” says Ran Ma, co-founder and CEO of Siren. “By investing in preventive technologies like ours, Mölnlycke is demonstrating real vision and leadership in helping patients avoid the debilitating consequences of diabetic foot ulcers. Their investment sends a clear message that prevention matters. By catching issues before they escalate, we can help patients stay healthy and independent, reduce unnecessary procedures, and ultimately make a real difference in their lives.”
Comments